Evidence implicating Eph receptor tyrosine kinases and their ephrin ligands (that together
make up the 'Eph system') in cancer development and progression has been accumulating …

Cell motility is regulated by multiple processes, including cell protrusion, cell retraction, cell–
matrix adhesion, polarized exocytosis and polarized vesicle trafficking, each of which is …

Mechanical cues from the extracellular matrix (ECM) regulate various cellular processes via
distinct mechanotransduction pathways. In breast cancer, increased ECM stiffness promotes …

More than 25 years of research and preclinical validation have defined EphA2 receptor
tyrosine kinase as a promising molecular target for clinical translation in cancer treatment …

Erythropoietin-producing hepatocellular receptor A2 (EphA2) is a key member of the
receptor tyrosine kinase (RTK) family, while YES Proto-Oncogene 1 (YES1) is a non …

Despite the success of treating EGFR-mutant lung cancer patients with EGFR tyrosine
kinase inhibitors (TKI), all patients eventually acquire resistance to these therapies. Although …

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive cancers and is
highly resistant to current treatments. ESCC harbors a subpopulation of cells exhibiting …

Yes‐associated protein (YAP) is a transcriptional coactivator that promotes cell proliferation,
stem cell maintenance and tissue homeostasis. The YAP activity is primarily regulated …

Overexpression of ANXA1 and EphA2 has been linked to various cancers and both proteins
have attracted considerable attention for the development of new anticancer drugs. Here we …

As we age, our tissues are repeatedly challenged by mutational insult, yet cancer
occurrence is a relatively rare event. Cells carrying cancer-causing genetic mutations …